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Telomerase activity is suppressed in normal somatic tissues but is activated in most cancer cells. We have previously found that all six
telomerase subunit proteins, including hTERT and hsp90 are needed for full enzyme activity. Telomerase activity has been reported
to be upregulated by protein kinase C (PKC), but the mechanism is not clear. In this study, we examined how PKC regulates
telomerase activity in head and neck cancer cells. PKC inhibitor, bisindolylmaleimide I (BIS), inhibited telomerase activity but had no
effect on the expressions of telomerase core subunits. RNA interference (RNAi) and in vitro phosphorylation studies revealed that
PKC isoforms a, b, d, e, z specifically involved in telomerase regulation, and the phosphorylation target was on hTERT. Treatment with
the hsp-90 inhibitor novobiocin dissociated hsp90 and hTERT as revealed by immunoprecipitation and immunoblot analysis and
reduced telomerase activity. Treatment with the PKC activator SC-10 restored the association of hsp90 and hTERT and reactivate
telomerase, suggesting that hTERT phosphorylation by PKC is essential for telomerase holoenzyme integrity and function. Analysis on
clinical normal and tumour tissues reveal that the expressions of PKC a, b, d, e, z were higher in the tumour tissues, correlated with
telomerase activity. Disruption of PKC phosphorylation by BIS significantly increased chemosensitivity to cisplatin. In conclusion, PKC
isoenzymes a, b, d, e, z regulate telomerase activity in head and neck cancer cells by phosphorylating hTERT. This phosphorylation is
essential for telomerase holoenzyme assembly, leading to telomerase activation and oncogenesis. Manipulation of telomerase activity
by PKC inhibitors is worth exploring as an adjuvant therapeutic approach.
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Telomerase is a specialised ribonucleoprotein enzyme responsible
for synthesising telomeric DNA at the end of chromosomes.
Human telomeres consist of hundreds to thousands of tandem
repeats of the sequence TTAGGG, which is essential for stabilising
the chromosome (Morin, 1989). The telomere length is progres-
sively shortened during cell replication, which is thought to be an
indicator of cell senescence. Telomerase activity is undetectable in
normal somatic cells, whereas telomere length is stabilised and
telomerase activity is detected in about 85% of cancer cells.
Reactivation of telomerase is thus believed to be involved in
cellular immortalisation and tumorigenesis (Counter et al, 1992;
Kim et al, 1994).
Telomerase is a holoenzyme consisting of several subunits
including hTR (human telomerase RNA), TEP1 (telomerase-
associated protein1), hTERT (human telomerase reverse tran-
scriptase), hsp90 (heat shock protein 90), p23, and dyskerin. hTR
functions as a template for telomere elongation (Feng et al, 1995).
TEP1 is thought to be associated with RNA and protein binding
(Nakayama et al, 1997). hTERT contains reverse transcriptase
motifs and functions as the catalytic subunit of telomerase (Linger
et al, 1997), while hsp90 and p23 are molecular chaperons which
bind to hTERT and contribute to telomerase activity (Holt et al,
1999). Dyskerin is thought to mediate the interaction with
telomerase ribonuclear protein and facilitate hTR processing or
assembly to form an active telomerase complex (Mitchell et al,
1999). Our previous study has shown that hTERT is regulated,
whereas the other components are expressed more constantly.
Although hTERT has a rate-limiting effect on enzyme activity, the
other telomerase subunits all participate in full enzyme activity
(Chang et al, 2002).
Several mechanisms by which telomerase activity is regulated
have been reported. At the transcriptional level, transcriptional
activators (c-myc, Sp1) and repressors (Mad1) regulate hTERT
expression and telomerase activity (Wu et al, 1999; Gunes et al,
2000; Kyo et al, 2000). Akt, c-Abl, and protein kinase C (PKC) have
all been shown to contribute to post-transcriptional regulation of
the enzyme activity by kinase phosphorylation (Kang et al, 1999;
Kharbanda et al, 2000; Yu et al, 2001). Our previous study found
that PKC regulated telomerase activity in nasopharyngeal cancer
cells (Ku et al, 1997). Recent studies on telomerase regulation by
PKC have shown that telomerase activation can be achieved by
both transcriptional and post-transcriptional effects on hTERT. It
has been demonstrated that telomerase in human breast cancer
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scells is regulated by PKC a through phosphorylation of hTERT (Li
et al, 1998). PKC z has been reported to regulate telomerase
activity through both transcription and post-transcriptional
mechanisms in nasopharyngeal cancer cells and peripheral T
lymphocytes during T-cell activation (Yu et al, 2001; Sheng et al,
2003). These results indicate that telomerase is regulated by
various PKC isoenzymes, perhaps depending on the specific cell
type or cell status.
Although several reports demonstrate the role of PKC in
telomerase regulation, exactly how it functions in different types
of cells and in carcinogenesis remains largely unknown. In this
study, we examined whether PKC regulates telomerase activity in
head and neck cancer cells and which PKC isoforms may be
involved. Since the integrity of telomerase holoenzyme is
important for telomerase full activity, we investigated whether
PKC plays a part in telomerase holoprotein structure.
MATERIALS AND METHODS
Chemicals
PKC inhibitor bisindolylmaleimide I (BIS), PKC activator SC-10
and hsp90 inhibitors novobiocin were all purchased from
Calbiochem (San Diego, CA, USA). BIS has been reported to
inhibit PKC function by competition for ATP binding, leading to
the failure of PKC phosphorylation on its substate (Yu et al, 2001).
SC-10 is a potent Ca
2þ-dependent PKC activator (Watson et al,
1992).
Patients and tissue samples
Human tissues used for this study were obtained from patients
with head and neck squamous cell carcinoma, admitted to the
Otorhinolaryngology or Head and Neck Surgery clinics at Chang
Gung Memorial Hospital (Taoyuan, Taiwan). Written informed
consent was obtained from all participating patients. Biopsies of
cancer and grossly normal mucosal tissues were obtained from
each subject before chemo- or radiotherapy. A portion of each
tissue sample was stored in liquid nitrogen until use for molecular
assay.
Cell culture, chemical treatment, and determination of cell
viability
The OEC-M1 oral cancer cell line was used (Yang et al, 2001). The
cells were cultured routinely in RPMI-1640 medium (Gibco BRL,
Rockville, MD, USA) supplemented with 10% fetal calf serum and
1% antibiotics at 371C in a humidified incubator containing 5%
CO2. OEC-M1 cell were seeded at a density of 1.2 10
6 per 100-mm
dish in complete medium. When the cells reached 60% confluence,
they were treated with the various experimental chemicals. Cell
viability was determined by staining with 0.25% trypan blue, with
the fraction of stain-negative cells taken as the surviving fraction.
Cellular protein extraction and analysis of telomerase
activity
Cell pellets were suspended in lysis buffer (10mM Tris-HCl, pH 7.4,
1m M MgCl2,1 m M EGTA, 0.5% CHAPS, 10% glycerol, 0.1mM
PMSF, 10mlml
 1 aprotinin, 10mgml
 1 leupeptin) and incubated
for 30min at 41C while being gently mixed. After centrifuging at
14000rpm for 30min at 41C, the supernatant was transferred to
fresh tubes for the telomerase activity assay. Protein concentra-
tions were determined using Coomassie Protein Assay Reagent
(Bio-Rad, CA, USA).
Telomerase activity was assayed with the telomeric repeat
amplification protocol-enzyme immunoassay (TRAP-EIA) as we
have previously described (Cheng et al, 1999). Telomerase activity
was determined based on the ability to produce telomere repeats
by using a PCR-based TRAP assay and measuring the PCR
products using an EIA-based assay. Briefly, 0.3mg of protein
extract was added to a TRAP reaction buffer and incubated at 251C
for 15min, followed by amplification by 30 cycles of PCR at 941C
for 30s, 551C for 30s, and 721C for 1min. After PCR, 5ml of the
PCR products were placed in streptavidin-coated wells and
incubated with 200ml of antidigoxigenin antibody conjugated with
horseradish peroxidase (10mUml
 1)a t3 7 1C for 30min in EIA
reaction buffer. After washing, enzyme reactions were initiated by
the addition of 200ml of tetramethylbenzidine substrate solution to
each well. After 10min, the reactions were stopped by the addition
of 50mlo f2 N HCl to each well. Colorimetric signals were
determined by measuring the absorbance at 450nm using an
automatic microwell reader.
RNA extraction and assay for telomerase subunit
expressions
The gene expression of each telomerase subunit (TEP1, hTERT,
hsp90 and p23) was analysed using a reverse transcriptase–
polymerase chain reaction (RT–PCR) assay that we have
previously described (Chang et al, 2002). Total RNA from cells
was isolated with TRIzol reagent (Gibco BRL) following the
manufacturer’s instructions. The concentration, purity, and
amount of total RNA were determined by ultraviolet spectro-
photometry. The reverse transcription reaction was performed by
incubation of a reaction mixture containing 300ng RNA, 100
pmole of poly-T oligonucleotide, 4U of reverse transcriptase, 10
units of RNase inhibitor, and 25mM dNTP in a total of 30ml
reaction buffer at 371C for 1h. PCR reactions were carried out with
30 cycles of denaturation at 941C for 40s, annealing at 561C for 40s
and extension at 721C for 1min. The PCR products were analysed
by 2% agarose gel electrophoresis, stained with ethidium bromide,
and visualised and photographed by illuminating with 254nm UV.
The photograph was scanned and the band intensities were
measured using densitometry.
Cytosol and nuclear protein extraction
Cell pellets were resuspended in 400ml of cold buffer (20mM
Hepes, pH 7.9, 150mM NaCl, 10% glycerol, 1mM EDTA, 1mM
EGTA, 1mM DTT, and 0.5mM PMSF) on ice for 15min. After
adding 25ml of 10% Nonidet P-40, cells were vortexes for 10s and
centrifuged at 14000rpm for 1min. The supernatant was
transferred to a fresh tube as the cytosolic fraction. To fractionate
nuclear protein, the nuclear pellet was resuspended in 50ml ice-
cold buffer (20mM Hepes, pH 7.9, 0.4 M NaCl, 1mM EDTA, 1mM
EGTA, 1mM DTT, and 1mM PMSF). After incubation at 41C for
15min with vigorously shaking, the nuclear extract was centri-
fuged at 14000rpm for 5min. The supernatant thus contained
nuclear protein, the concentration of which was determined with
Coomassie Protein Assay Reagent (Bio-Rad, CA, USA).
Immuoprecipitation and immunoblot analysis
The immunoprecipitation and immunoblot methods used were
similar to the protocols suggested by the manufacturer (Santa Cruz
Biotech, CA, USA). Briefly, prior to immunoprecipitation, 30ml
protein A/protein G sepharose beads (Santa Cruz Biotech)
conjugated with 4mg of specific antibodies (goat polyclonal anti-
hTERT, clone SC-7214 and mouse monoclonal anti-hsp90, Santa
Cruz Biotech) were washed with 1ml RIPA buffer (20mM Tris-HCl,
pH 7.4, 150mM NaCl, 0.5% Nonidet P-40, 0.1% SDS, 1%
deoxycholate) followed by 1ml blocking solution (5% BSA,
0.02% calf thymus DNA, 0.3% CHAPS). For immunoprecipitation,
1mg of the cellular or nuclear protein extract was incubated with
30ml conjugated protein A/protein G sepharose beads and
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sincubated while rotating for 4h at 41C. The beads were collected by
centrifugation at 3000rpm for 5min at 41C and washed three times
with 0.6ml of cool RIPA buffer. Finally, the beads were collected by
centrifugation at 3000rpm for 5min at 41C, resuspended in 20mlo f
a sample buffer (25mM Tris-HCl, pH 6.8, 10% glycerol, 2% SDS,
5% b-mercaptoethanol), and subjected to immunoblot analysis.
Beads conjugated with nonimmunised goat serum IgG were
used as a negative control to determine the specific effect of
immunoprecipitation.
For immunoblot analysis, cellular protein extract was used for
determination of PKC isoenzymes, and nuclear protein extract was
used for examination of hTERT level. Total of 20mg of proteins in
the sample buffer or 3ml of the immunoprecipitated samples were
prepared. All samples were boiled at 951C for 5min, and subjected
to 10% SDS-polyacrylamide gel for electrophoresis. The protein
image on the electrophoretic gel was transferred to a nitrocellulose
membrane and blocked with 5% nonfat milk in PBST solution
(phosphate buffer saline plus 0.1% Triton X-100). After being
washed twice with PBST, the membrane was incubated with a
proper dilution of first antibodies (for PKC isoforms: PKC a, bI,
bII, g, d, e, z and Z, Santa Cruz Biotechnology; and for pan-PKC
phosphosubstrate, Cell Signaling, New England BioLabs, Beverly,
MA, USA) at room temperature for 2h. The membrane was washed
again and incubated with anti-mouse IgG or anti-rabbit IgG
antibody conjugated with horseradish peroxidase. The membrane
was treated with ECL developing solution (Amersham Pharmacia
Biotech, New Territories, Hong Kong) and exposed to X-ray film.
Actin expression was used as an internal control to determine the
relative expression of PKC isoenzymes.
In vitro phosphorylation assay
A total of 20mg of BIS-treated cell or nuclear lysates was mixed
with 25ng of a specific PKC isoenzyme (Upstate biotechnology,
NK, USA) in a final volume of 25ml containing 6ml of assay
dilution buffer (40mM MOPS, pH 7.2, 50mM b-glycerophosphate,
2m M sodium orthovandate, 2mM dithiothreitol, 2mM CaCl2), 5ml
lipid activator (0.5mgml
 1 phosphotidylserine, 0.05mgml
 1
diacylglycerol) and 5ml ATP mixture (75mM MgCl2, 500mM ATP,
100mCi [g-P
32]-ATP). After incubation at 301C for 10min, cellular
proteins were extracted for analysis. To determine the effect of
PKC phosphorylation on telomerase activity, TRAP-EIA assay was
performed as described above. To determine whether hTERT is the
PKC phosphorylation target, anti-hTERT antibodies were used to
immunoprecipitate the phosphorylated protein. After SDS–PAGE
separating the precipitated proteins, the gel was subjected to
autoradiography.
RNA interference cloning and cellular transfection
pTOPO-U6 vector was used for PKC-RNAi construction as we have
described previously (Tseng et al, 2003). RNAi oligonucleotides for
PKC a, b, g, d, e, z, and Z RNAi are listed in Table 1. The RNAi
oligonucleotides were annealed and ligated to pTOPO-U6 vector
corresponding to the blunt end and the overhang that matched the
EcoRV- and BbsI-digested pTOPO-U6. The ligation between the
annealed oligonucleotides and pTOPO-U6 at the EcoRV and BbsI
cloning sites generated PKC-RNAi plasmid. OEC-M1 cells were
transfected with a mixture of 3mg plasmid DNA and 3ml
Lipofectamint 2000 (Invitrogen, CA, USA) in 3ml OPTI-MEM
medium (Gibco) and incubated at 371Ci n5 %C O 2 for 12h. After
transfer to complete culture medium, the cells were continuously
incubated for 1–3 days. Cellular proteins were determined by
immunoblot and telomerase activity was measured by TRAP-EIA
assay.
RESULTS
BIS inhibited telomerase activity but had no effect on gene
expression
To investigate the mechanism by which PKC regulates telomerase
activity leading to cancer formation, the PKC specific inhibitor BIS
was used. In this study, we first examined the effects of BIS in
OEC-M1 cells. OEC-M1 cells were treated with various amount of
BIS (0 to 50mM) for 48h. Cellular proteins were extracted for the
determination of PKC protein expressions and activity. The
expression of PKC isoenzymes a, bI, bII, g, d, e, z, and Z was
determined by immunoblot analysis using specific PKC isoenzyme
antibodies. Figure 1 shows the representative results of cells
treated with 40mM of BIS. At this dose, cell viability is
approximately 75%. As shown in Figure 1A, all PKC isoenzymes
were reduced in BIS-treated cells, ranging from 13% (PKC-g)t o
70% (PKC-z) reduction. Enzymatic activity was determined by
examining the amount of PKC- phosphosubstrates by immunoblot
analysis using anti-PKC phosphosubstrate antibody. As shown in
Table 1 List of RNAi oligonucleotides for each PKC isoenzyme
Gene Sequence
PKC a 50-CGACTGGGAAAAACTGGAGAAGCTTGTCCAGTTTTTCCCAGTCG-30
50-GGATCGACTGGGAAAAACTGGACAAGCTTCTCCAGTTTTTCCCAGTCG-30
PKC b 50-GAAGATGAACTCTTCCAAGAAGCTTGTTGGAAGAGTTCATCTTC-30
50-GGATGAAGATGAACTCTTCCAACAAGCTTCTTGGAAGAGTTCATCTTC-30
PKC g 50-TCTTTCCCCAGAGGCTCCGAAGCTTGGGAGCCTCTGGGGAAAGA-30
50-GGATTCTTTCCCCAGAGGCTCCCAAGCTTCGGAGCCTCTGGGGAAAGA-30
PKC d 50-GTGGTCCTGATCGACGACGAAGCTTGGTCGTCGATCAGGACCAC-30
50-GGATGTGGTCCTGATCGACGACCAAGCTTCGTCGTCGATCAGGACCAC-30
PKC e 50-GATGACGTGGACTGCACAGAAGCTTGTGTGCAGTCCACGTCATC-30
50-GGATGATGACGTGGACTGCACACAAGCTTCTGTGCAGTCCACGTCATC-30
PKC Z 50-GGAACTTTCAGATATCAAGAAGCTTGTTGATATCTGAAAGTTCC-30
50-GGATGGAACTTTCAGATATCAACAAGCTTCTTGATATCTGAAAGTTCC-30
PKC z 50-TACACTCCTGCTTCCAGAGAAGCTTGTCTGGAAGCAGGAGTGTA-30
50-GGATTACACTCCTGCTTCCAGACAAGCTTCTCTGGAAGCAGGAGTGTA-30
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sFigure 1B, less phosphosubstrate was detected in BIS-treated
protein extract, indicating decreased PKC activity in BIS-treated
cells. These results indicated that BIS inhibits PKC protein
expression as well as enzyme activity.
The effect of BIS on telomerase activity and gene expression
were examined. OEC-M1 cells were incubated with various amount
of BIS (0 to 50mM) for 48h and the telomerase activity was
determined by TRAP-EIA assay. As shown in Figure 1C, telomer-
ase activity was inhibited in a dose-dependent manner by BIS, with
an approximately 50% decrease in telomerase activity induced by
treatment with 40mM of BIS. In order to examine whether the loss
of telomerase activity resulted from the suppression of telomerase
gene expression, transcriptional levels of the telomerase core
subunit genes hTERT, TEP1, hsp90 and p23 were determined by
RT–PCR. As shown in Figure 1D, BIS had no effect on core
telomerase gene expression. This indicates that PKC-inhibited
telomerase activity in head and neck cancer cells does not occur
through the suppression of gene expression. It more likely based
on a post-transcriptional regulatory mechanism.
PKC a, b, d, e, and f are involved in telomerase regulation
through phosphorylation mechanism
To examine which PKC isoenzyme is involved in telomerase
regulation, telomerase activity was determined after specific
suppression of PKC protein expression by RNA interference
(RNAi). OEC-M1 cells were transfected with specific PKC-RNAi
plasmid for 48h and the cellular protein levels were determined by
immunoblot. As shown in Figure 2A, all seven PKC isoenzymes
(a, b, g, d, e, z and Z) were successfully suppressed by specific RNAi.
Telomerase activity, however, was only inhibited by PKC a, b, d, e
and z suggesting that these PKC isoenzymes involved in telomerase
regulation (Figure 2B). To further confirm this observation as well
as the mechanism of BIS suppression on telomerase activity, an in
vitro phosphorylation experiment was performed. OEC-M1 cells
were treated with 40mM BIS for 48h. Cellular protein was extracted
and subjected to in vitro phosphorylation by specific PKC
isoenzymes, followed by determination of telomerase activity. As
shown in Figure 2C, PKC-a, bI, bII, d, e and z but not g and Z,
restored BIS-suppressed telomerase activity, consistent with the
finding in the RNAi experiments. In fact, these isoenzymes
produced a even higher level of enzyme activity than the control.
This may be because endogenous telomerase in OEC-M1 cells was
not fully activated. Phosphorylation by exogenous PKC may confer
full enzyme activity, including the inactivated telomerase mole-
cules present in the cells.
hTERT was the target of PKC phosphorylation
Since, we and others have previously demonstrated that hTERT is
a regulated, rate-limiting telomerase subunit protein, we examined
whether it was a target of PKC phosphorylation. Nuclear proteins
from OEC-M1 cells were phosphorylated in vitro by specific PKC
isoenzymes a, bI, bII, d, e, z using [g-P
32]-ATP. Protein samples
were immunoprecipitated by hTERT antibody. Samples were then
subjected to immunoblot analysis or autoradiography. Results are
shown in Figure 3. In each sample, the protein immunoblotted by
hTERT antibody served as an internal control to ensure the
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Figure 1 Effects of PKC inhibitor, BIS, on telomerase activity and the telomerase subunit expressions. OEC-M1 cells were treated with 40mM (A, B, D)o r
various amounts (B) of BIS for 48h. (A) Effect of BIS on PKC isoenzyme expressions. Eight PKC isoenzymes (a, bI, bII, g, d, e, z, Z) were determined by
immunoblot, as indicated at the left of the figure. (B) Effect of BIS on PKC phosphorylation activity. PKC activity was determined by examining the amount of
PKC-phosphosubstrate using pan-antibody by immunoblot analysis. C: Control, without drug treatment; BIS: BIS-treated cells. (C) Effect of BIS on
telomerase activity. Telomerase activity was determined by TRAP-EIA as described in the materials and methods. (D) Effect of BIS on the expressions of
telomerase subunits. Telomerase subunits, hTERT, hsp90, TEP1 and p23 were determined by RT–PCR as indicated on the left of the figure. Actin
expression was determined as an internal control.
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spresence of hTERT protein in the samples. Proteins without
phosphorylation (lanes 1 and 2) or those immunoprecipitated by
preimmune goat IgG (lane 9), which had no detectable band on
autoradiography, served as a negative control. The autoradio-
graphy data (lanes 3–8) indicate that all PKC phosphorylated
proteins were immunoprecipitated by hTERT, indicating that
hTERT is the target of PKC phosphorylation. Taken together, all
the above studies indicate that PKC phosphorylates hTERT and is
thus responsible for telomerase enzyme activity.
PKC phosphorylation was essential for telomerase
holoprotein integrity and telomerase activity
Since we have previous demonstrated that telomerase holoprotein
integrity is crucial for full enzyme activity (Chang et al, 2002), we
investigated whether PKC phosphorylation had an effect on
holoenzyme integrity. To address this question, cells were exposed
to a hsp90 inhibitor, novobiocin (Haendeler et al, 2003), to
disassociate hsp90 from other proteins. A PKC activator, SC-10
was also used to examine the potential influence of PKC
phosphorylation. As shown in Figure 4A, more phosphosubstrate
was detected in SC-10-treated proteins, indicating that PKC
activity increased after SC-10 treatment. Immunoprecipitation
and immunoblot analysis were used to examine the status of
protein association. OEC-M1 cells were treated with novobiocin for
24h. Cells were harvested or continuously cultured with SC-10 for
an additional 24h. As shown in Figure 4B, a hTERT-immuno-
blotted band was detected after immunoprecipitation by hsp90,
indicating the association of these two proteins (lane 1). After
specific inhibition of PKC by RNAi, this association was disrupted
(lane 2), suggesting that PKC phosphorylation plays a crucial role
in maintaining the integrity of the telomerase holoenzyme. The
association of hsp90 and hTERT was disrupted (lane 3), however,
was restored after induction of PKC function by SC-10 (lane 4),
suggesting PKC phosphorylation promotes interaction of hsp90
with hTERT.
To examine whether the maintenance of telomerase holoprotein
integrity by PKC is crucial for enzyme function, the enzyme
activity was determined after disruption of the hTERT-hsp90
association by novobiocin and its reassociation by PKC activator
SC-10. After OEC-M1 cells were treated with novobiocin for 24h,
cells were harvested or continuously cultured with SC-10 for
additional 24h. Telomerase activity was determined. Results were
shown in the Figure 4C. Telomerase activity was suppressed after
disruption of the holoprotein structure by novobiocin (lane 3),
similarly as found in the treatment of PKC-RNAi (lane 2),
indicating the telomerase holoprotein integrity was crucial for
enzyme activity. However, the novobiocin-inhibited activity was
restored by SC-10 (lane 4), consistent with the findings in the
previous experiments on protein interaction (Figure 4B). Thus, the
role of PKC phosphorylation in telomerase activity appears to
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Figure 2 Effects on telomerase activity by specific PKC isoenzymes. (A)
OEC-M1 cells were transfected with specific PKC-RNAi plasmids for 48h.
Immunoblot analysis to determine the protein expression levels of each
PKC isoenzyme. Actin gene expression was measured as an internal
control. Actin expression remained consistent in every transfected sample.
In this figure, the results of PKC a-RNAi transfection are shown as
representative of all the RNAi experiments. C: control cells without plasmid
transfection, V: cells transfected with vector, RNAi: cells transfected with
specific PKC-RNAi plasmid as indicated on the left of the figure. (B)
Telomerase activity was determined after transfection with specific PKC-
RNAi plasmids as indicated on the bottom of the figure. (C) OEC-M1 cells
were treated with 40mM BIS for 48h. Cell lysates were subjected to in vitro
phosphorylation by specific PKC isoenzymes as indicated, followed by
determination of telomerase activity. *Statistical significance using Student’s
t-test (Po0.05 of two-sided test).
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Figure 3 In vitro phosphorylation study for the target molecule hTERT.
Nuclear proteins were phosphorylated using [g-P
32]-ATP by specific PKC
isoenzymes as indicated on the top of the figure. Protein samples were
immunoprecipitated by hTERT antibody. Samples were then subjected to
autoradiography or immunoblot analysis. Proteins without phosphorylation
(lanes 1 and 2) or immunoprecipitated with pre-immune goat IgG (IgG)
(lane 9) were used as negative controls. An immunoblot of hTERT for each
sample served as an internal control. Autoradiography data for immuno-
precipitated samples demonstrate that hTERT molecules were phosphory-
lated by the PKC isoenzymes.
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soccur through promoting telomerase holoenzyme assembly and/or
maintaining the holoprotein integrity.
PKC isoenzymes a, b, d, e and f were overexpressed in
tumour samples, correlating with a high level of
telomerase activity
To understand the function of PKC isoenzyme in the carcino-
genesis of head and neck cancers and the potential association with
telomerase activity, four tumour samples from patients with head
and neck squamous cell carcinoma and their respective grossly
normal mucosa tissues were obtained for study. PKC isoenzymes
were determined by immunoblot analysis and telomerase activity
was measured by TRAP-EIA method. Results of PKC isoenzyme
expression and the relative level of telomerase activity normalised
with that in OEC-M1 cells are shown in Figure 5A. The average
quantitative results of each PKC isoenzyme normalised with actin
levels and average level of telomerase activity were shown in
Figure 5B. Differential concentrations of the various isotypes were
found. On average, PKC a, bI, bII, d, e and z had greater than two-
fold overexpression in the tumour samples compared to the
normal tissue counterparts, which were correlated with an increase
in telomerase activity. This was not true for PKC g or Z. These
clinical data further support our findings that PKC a, b, d, e and z
participate in the carcinogenesis of head and neck cancer,
probably by the way of telomerase activation.
Inhibition of telomerase through dephosphorylating PKC
increases chemosensitivity to cisplatin
To examine whether the inhibition of telomerase through depho-
sphorylating PKC influences the chemosensitivity of head and
neck cancer cells, OEC-M1 cells were treated with 40mM BIS for
48h, followed by administration of various doses of cisplatin (0, 3
or 10mgml
 1) for an additional 12h. Cell viability was determined
to assess the chemosensitivity to cisplatin (Figure 6). There was a
minimal effect on cell death at a dose 3mgml
 1 of cisplatin in the
control group. There was, however, a significant decrease in cell
viability after BIS treatment, an effect more apparent with
10mgml
 1 of cisplatin. At this concentration, 63% cell viability
was observed in the control group compared with only 10% of cells
surviving with BIS treatment. These results indicate that inhibition
of telomerase activity by BIS significantly increases the sensitivity
to cisplatin.
DISCUSSION
In this study, we investigated how PKC regulates telomerase
activity in head and neck cancer cells. Possible mechanisms of PKC
in the regulation of telomerase activity include enhanced expres-
sion of telomerase genes through a PKC-dependent signal path-
way, phosphorylation of telomerase subunit proteins, or both. We
found that PKC regulation of telomerase activity in these cells
occurs through phosphorylation (Figure 2C) but not by influen-
cing the expression of telomerase core subunits (Figure 1). Our
RNAi transfection studies revealed that specific PKC isoforms,
namely a, b, d, e and z, involved in regulating telomerase activity
(Figure 2B), which was in agreement with the findings in clinical
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Figure 4 Effect of PKC phosphorylation on telomerase holoprotein
integrity and the enzyme activity. (A) After treatment with 10mM SC-10,
PKC activity was determined by examining the amount of PKC-
phosphosubstrates using pan-antibody immunoblot analysis. (B) Associa-
tion study of hTERT-hsp90 and the influence of PKC phosphorylation.
Lanes 1 and 2: Nuclear proteins from OEC-M1 cells with or without PKC-
RNAi plasmid transfection were extracted and subjected to immuno-
precipitation and immunoblot. Lanes 3 to 4: OEC-M1 cells were treated
with 300mM novobiocin for 24h to disrupt the hsp-hTERT association.
Cells were harvested or continuously cultured with 10mM SC-10 for an
additional 24h (novobiocinþSC-10). Nuclear proteins were subjected to
immunoprecipitation by hsp90 followed by immunoblot by hTERT or
hsp90 (as control). (C) Alterations of telomerase activity after hTERT-
hsp90 disruption and reassociation. Lanes 1 and 2: Cellular proteins from
OEC-M1 cells with or without PKC-RNAi plasmid transfection were
extracted for determination of telomerase activity by TRAP-EIA. Lanes 3 to
4: OEC-M1 cells were treated with 300mM novobiocin for 24h to disrupt
the hsp-hTERT association. Cells were harvested or continuously cultured
with 10mM SC-10 for an additional 24h. Cellular proteins were extracted
for determination of telomerase activity.
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scancer tissue specimens (Figure 5). In vitro phosphorylation
experiments further demonstrated that the target of PKC
isoenzymes is the hTERT molecule (Figure 3).
Although hTERT is a crucial component of telomerase and
subject to regulation, the association of other telomerase subunits,
such as chaperone protein hsp90, is required for enzyme activity
(Holt et al, 1999; Chang et al, 2002). The binding of hsp90 to
hTERT was been shown to be essential for assembly of the
telomerase complex and its activity (Holt et al, 1999). However, the
underlying mechanism is not fully elucidated. The present study
has demonstrated that specific inhibition of PKC by RNAi
transfection disrupts the hTERT-hsp90 association (Figure 4),
suggesting that PKC affects protein interaction. Furthermore, an
hsp90 inhibitor, novobiocin, interfered with hTERT-hsp90 inter-
action, suggesting hTERT association is in close to the vicinity of
novobiocin binding site within hsp90. The protein association was
restored after treatment with the PKC activator SC-10, further
evidence that PKC phosphorylation results in hTERT-hsp90
interaction, a key function in maintaining the integrity of the
telomerase holoenzyme. However, since hsp90 chaperone is known
to facilitate the folding and assembling of several proteins, this
molecule maybe also involve in interaction with other telomerase
subunits, presumably at varying sites other than hTERT binding
domain. To summarise our findings, the PKC isoenzymes a, bI,
bII, d, e and z regulate telomerase activity in head and neck cancer
cells through phosphorylation of hTERT, a holoenzyme assembly
step that is essential telomerase activation and oncogenesis.
While phosphorylation of hTERT is essential for telomerase
activation, PKC is likely not the only enzyme responsible for
phosphorylating this molecule. Telomerase activity in human
breast cancer cells is markedly inhibited by treatment with protein
phosphatase 2A (Li et al, 1998). Protein kinase Akt also activates
telomerase by phosphorylating hTERT in melanoma and epithelial
cells (Kang et al, 1999; Breitschopf et al, 2001). A potential
mechanism of telomerase regulation through hTERT phosphoryla-
tion linked to nuclear localisation of the enzyme has been reported
in T lymphocytes during cell activation (Liu et al, 2001). Recently,
the association of hTERT with hsp90 and Akt in concert with
hTERT phosphorylation has been found in human endothelial
cells, suggesting that Akt phosphorylation also plays a role in
assembly of the holoprotein (Haendeler et al, 2003). Our results,
demonstrate the mechanism by which PKC functions in main-
taining telomerase holoenzyme integrity and hence activation in
head and neck cancer cells. Given the common requirement of
telomerase activity in cancer cells because of the enzymes
pleiotropic functions, it is not surprising that hTERT appears to
be regulated by many kinases, PKC and Akt among them. It may
well be that the principle enzymes involve in activation of
telomerase vary with specific tissues or specific cellular states
and perhaps participate in various molecular mechanisms.
Our finding that PKC isoenzymes a, b, d, e and z are correlated
with increased telomerase activity in clinical head neck tumour
samples (Figure 5). Although the data set is few, these results
implicate the significance of these molecules in carcinogenesis in
head and neck cancer. PKC isoenzymes have been found to display
variable expression profiles depending on specific cancer type. For
example, PKCa and b has shown over-expressed in both high
grade of prostate, gastrointestinal tract and head neck cancers
(Koren et al, 2004; Lahn et al, 2004; Martinez-Gimeno et al, 1995).
In contrast, hepatocellular and breast cancer display a down-
regulation of PKCa, and bladder cancer shows a down regulation
of PKCb (Tsai et al, 2000; Kerfoot et al, 2004; Varga et al, 2004).
However, vast majority of the studies have demonstrated the
functions of PKC a and b associated with the increased invasion
and proliferation activity, while the inhibition of these PKC
isoenzymes effectively reverses the malignant phenotype
(Hanauske et al, 2004; Jiang et al, 2004; Koivunen et al, 2004).
Our finding that PKC isoenzymes a and b overexpressed in head
neck cancers is in agreement with most findings that these two
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Figure 5 Relative levels of telomerase activity and the expressions of
PKC isoenzymes in normal and tumour tissues. Four pairs of normal (N)
and tumour (T) tissues from head and neck cancer patients were
examined. Each sample is indicated at the top of the figure. (A) The protein
expression was determined by immunoblot analysis and is indicated at the
left of the figure. Actin protein expression was used as an internal control.
Telomerase activity in each sample was determined by TRAP-EIA and was
normalised with that in the OEC-M1 cell lines. Relative levels of telomerase
activity (%TS) are indicated at the bottom of the figure. (B) Average of
telomerase activity and PKC isoenzyme expression in tumour and normal
tissues. After quantitation of the immunoblot densities in each sample, the
levels of PKC isoenzymes were normalised with their respective actin level
to calculate the relative expression. Average of telomerase activity in each
sample was also determined as indicated. *Statistical significance using
student t-test (Po0.05 of two-sided test).
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sPKC isoenzymes play positive regulatory roles in carcinogenesis.
Regarding PKCd, the expression of this molecule in cancers has
not been extensively studied. However, similarly to classical PKC
(a, b), PKCd was shown either upregulated (hepatocellular cancer)
or downregulated (urinary bladder cancer) in various cancer
tissues (Tsai et al, 2000; Varga et al, 2004). Our finding that PKCd
upregulated in cancer tissues in head neck cancer was consistent
with the finding in hepatoma. The most important function of
PKCd is thought to promote apoptosis in response to DNA damage
or oxidative stress in cells (Basu, 2003). This enzyme activity is
known to result in many proapoptotic signals such as increased
expression and stability of p53, release of mitochondrial cyto-
chrome c, or activation of c-Abl (Majumder et al, 2000; Sun et al,
2000; Abbas et al, 2004). Since our head neck cancer patients have
betel quid chewing habit (Chen et al, 2003), a potent carcinogen of
oral cancer, our finding of PKCd overexpressed in the cancer
patients may be explained triggered by the chemical stimulus.
Aside from apoptotic induction, in the present study, PKCd was
also found activation of hTERT and correlation with telomerase
activity in tissues. Therefore, PKCd may function as a molecular
sensor, which participates in the transformation of cell to be
immortalised under survival conditions and executes the death of
severe damaged cells. As for PKC e and z, although their cellular
function still obscure, their expressions have been reported in
various cancers. PKCe has been shown upregulated in head neck,
brain and prostate cancers (Xiao et al, 1994; Martinez-Gimeno
et al, 1995; Sharif and Sharif, 1999; Koren et al, 2004), whereas
downregulated in pancreatic cancer (Evans et al, 2003). PKCz have
been shown upregulated in brain, liver and bladder cancers (Xiao
et al, 1994; Tsai et al, 2000; Varga et al, 2004). Despite various
reports, most of the studies favour the roles of PKC e and z in the
positive regulation of cancer growth, which are consistent with our
findings of overexpression in head neck cancer tissues. Perhaps,
the reactivation of telomerase through PKC phosphorylation by
these isoenzymes may be one of the mechanisms leading to the
carcinogenesis.
Understanding the mechanisms underlying oncogenesis has
wide-ranging implications for targeting the treatment of cancer. In
particular, treatment strategies directed at tumour-specific func-
tions, such as activation of telomerase, should minimise cytotoxic
effects on normal cells. PKC dephosphorylation enhanced the
chemosensitivity to cisplatin of cancer cells in vitro (Figure 6) is an
example of such an approach. Our study provides a foundation for
further investigation into the manipulation of telomerase activity
as a potential therapeutic modality.
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